Table 1.
Previous studies
| Author and year | Tumour type | Cut off value for IHC |
Low MGMT protein expression predictive of: |
MGMT IHC compared to molecular gold standard | Molecular test | Correlation between IHC and molecular test | |
|---|---|---|---|---|---|---|---|
| Progression free survival (PFS) | Overall survival (OS) | ||||||
| Nakasu et al. 2004 [7] |
69 high-grade gliomas (grades III and IV) |
10% |
- |
Yes |
No |
- |
- |
| Brell et al. 2005 [11] |
93 anaplastic gliomas: 75 AAs and 18 with oligodendroglial component |
5% |
No |
Yes |
Yes |
MS-PCR |
No |
| Chinot et al. 2007 [21] |
28 GBMs |
35% |
Yes |
Yes |
No |
- |
- |
| Capper et al. 2008 [22] |
75 primary GBMs |
15% |
Yes – median survival |
No |
- |
- |
|
| Preusser et al. 2008 [6] |
164 GBMs |
10% |
- |
No |
Yes |
MS-PCR |
Poor agreement |
| Rodriguez et al. 2008 [23] |
50 GBMs |
10% |
No |
No |
Yes |
MS-PCR |
No |
| Karayan-Tapon et al. 2010 [24] |
81 GBMs |
15% |
No |
No |
Yes |
MS-PCR |
- |
| SQ-PCR |
No |
||||||
| Pyrosequencing |
Yes |
||||||
| Q-RT-PCR |
Yes |
||||||
| Quillien et al. 2012 [5] | 100 GBMs | 23% | Yes | Yes | No | - | - |
The table shows previous studies where MGMT IHC has been performed. The cut-off value was the percentage of MGMT-positive tumour cell nuclei (assessed by eye). The correlation of IHC with progression-free survival (PFS) and overall survival (OS) and comparison with a molecular gold standard (where applied) are also shown.
Abbreviations: AA anaplastic astrocytoma, GBM glioblastoma multiforme, MS-PCR methylation-specific polymerase chain reaction, Q-RT-PCR quantitative real-time polymerase chain reaction, SQ-PCR semi-quantitative polymerase chain reaction.